Engage Therapeutics
Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 in Summit, New Jersey, developing treatments for epilepsy. The privately held firm has raised $23.6M in venture capital led by TPG Biotech.
- Company typePublic
- Founded2007
- HeadquartersSummit, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Engage Therapeutics does
Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 and headquartered in Summit, New Jersey. The company is focused on developing therapeutic solutions for epilepsy, operating within the broader neurological and autoimmune drug development space. Per the firmographic data, Engage Therapeutics runs a deliberately lean organization of 1-10 employees, consistent with a venture-backed, asset-focused biotech structure.
The company was capitalized at founding by a $23.6 million venture financing closed in September 2017, led by TPG Biotech with participation from Adage Capital Management, Granite Point Capital, LifeSci Venture Partners, and Lumira Ventures. The founding executive team consists of Greg Mayes as President, CEO, and Founder, with Heath Lukatch serving as Chairman. The company remains privately held, and no commercial products, pricing, partnerships, or revenue figures specific to Engage Therapeutics are disclosed in the available input data.
Note on data hygiene: a substantial portion of the input aggregates material pertaining to UCB S.A., a publicly traded Belgian biopharmaceutical company with operations across dozens of countries. That material — including UCB's revenue disclosures, global footprint, Candid Therapeutics acquisition, UCBCares service, and sub-brand portfolio — describes a separate entity and is not attributable to Engage Therapeutics in this analysis.
Engage Therapeutics firmographics
Firmographics- Name
- Engage Therapeutics
- Legal name
- UCB S.A.
- Website
- https://engagetherapeutics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Engage Therapeutics is a clinical-stage pharmaceutical company founded in 2017 in Summit, New Jersey, developing treatments for epilepsy. The privately held firm has raised $23.6M in venture capital led by TPG Biotech.
- Ownership category
- akta.pro rank
Engage Therapeutics industry classification
Industry- Product category
- Epilepsy Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Epilepsy & Seizure Disorders (HLAKAIAB)
Keywords
Where Engage Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Summit
- HQ country
- United States
- HQ region
- North America
Markets served
Engage Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Distribution channels1 record
Marketing channels7 records
Engage Therapeutics product offering
Product offeringCore offering
Engage Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic drug candidates for epilepsy. The company focuses on advancing treatments for seizure management through clinical development of neurological therapies, operating from its Summit, New Jersey headquarters with a small team (1-10 employees).
Differentiator
Problem solved
Functional benefit
Brands
- UCBCares: A personalized service offered by UCB to support people living with a disease and healthcare professionals during their treatment journey with a UCB medicine
- UCB Ventures
- UCB Community Health Fund
Products and services
- Epilepsy Clinical Development Program Clinical-stage drug development program advancing therapeutic candidates for the treatment of epilepsy and seizure-related neurological conditions. Targeted at patients living with severe seizure disorders; the program operates at a pre-commercial, clinical-stage phase with therapeutic candidates advancing through clinical development.
Companies that use Engage Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Engage Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Engage Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Candid TherapeuticscoreUCB completed acquisition of Candid Therapeutics to strengthen its next-generation immunology pipeline. This strategic acquisition enhances UCB's immunology portfolio and research capabilities.
Scale indicators1 record
Recent moves3 records
Expansion highlights2 records
Engage Therapeutics competitors and assessment
Company assessmentDirect peers
- Xenon Pharmaceuticals: Clinical-stage neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy and other neurological conditions. Comparable to Engage in therapeutic area and clinical development stage.
- Marinus Pharmaceuticals: Clinical-stage CNS biopharmaceutical company focused on seizure disorders, including status epilepticus and rare epilepsies. Directly comparable to Engage in therapeutic area, development stage, and target patient population.
- Longboard Pharmaceuticals: Clinical-stage biopharmaceutical company developing transformative medicines for neurological diseases, with a focus on rare and severe epilepsies. Closely comparable to Engage in stage, therapeutic focus, and capital structure.
- SK Life Science: Specialty CNS pharmaceutical company with a focused epilepsy franchise (e.g., cenobamate/XCOPRI). Directly comparable as a neurology-focused company targeting the same patient population as Engage.
Broad incumbents
- Pfizer: Global pharmaceutical company with a historical epilepsy franchise (e.g., Lyrica, Neurontin) and broad CNS capabilities. Comparable as a large pharma incumbent with neurology depth and acquirer potential.
- UCB: Global biopharmaceutical leader with major epilepsy franchise (Vimpat, Keppra) and broad CNS pipeline. Comparable as a large incumbent in Engage's therapeutic area with potential acquirer profile.
- Eisai: Global pharmaceutical company with a strong neurology franchise including the epilepsy treatment Fycompa (perampanel). Comparable as an established player with deep epilepsy commercial reach.
- Jazz Pharmaceuticals: Global biopharmaceutical company with an established neurology franchise including epilepsy treatments (e.g., Epidiolex). Comparable to Engage as a larger player in the same therapeutic space with overlapping target indications.
- Lundbeck: Global pharmaceutical company specializing in brain diseases, including epilepsy. Comparable as a neurology-focused incumbent with potential strategic interest in Engage's therapeutic area.
Regional players
- BIAL: Portuguese pharmaceutical company with a focused neurology franchise including epilepsy (e.g., Zebinix). Comparable as a smaller, neurology-focused peer with established epilepsy commercial infrastructure in select geographies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Engage Therapeutics social profiles
Digital presenceEngage Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Engage Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Engage Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Engage Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Engage Therapeutics
What does Engage Therapeutics do?
Engage Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic drug candidates for epilepsy. The company focuses on advancing treatments for seizure management through clinical development of neurological therapies, operating from its Summit, New Jersey headquarters with a small team (1-10 employees).
Is Engage Therapeutics a public or private company?
Engage Therapeutics is a public company. It is classified as venture growth investor backed and is currently operating.
When was Engage Therapeutics founded?
Engage Therapeutics was founded in 2007. It employs 1 to 10 people.
Where is Engage Therapeutics based?
Engage Therapeutics is headquartered in Summit, United States, in the North America region.
Who are Engage Therapeutics's main competitors?
Direct peers on record are Xenon Pharmaceuticals, Marinus Pharmaceuticals, Longboard Pharmaceuticals and SK Life Science. Broad incumbents are Pfizer, UCB, Eisai, Jazz Pharmaceuticals and Lundbeck. BIAL is listed as a regional player.
Does Engage Therapeutics have an API?
No public API is recorded for Engage Therapeutics.
What industry is Engage Therapeutics in?
Engage Therapeutics's product category is Epilepsy Therapeutics. Its primary akta.pro industry code is HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 32541 and its SIC code is 2834.